Introducing Internal Host Component to Thermally Activated Delayed Fluorescence Emitter for Efficient NIR Nondoped Organic Light-Emitting Diodes.

Developing thermally activated delayed fluorescence (TADF) near-infrared (NIR) organic light-emitting diodes (OLEDs) based on nondoped emitting layers is intriguing yet challenging, limited by low exciton utilization and notorious concentration quenching. Herein, a facile strategy is proposed to address this issue by incorporating an internal host component onto a traditional donor (D)-acceptor (A)-type red TADF molecule. A proof-of-concept emitter with an internal host is accordingly developed as well as a control one without an internal host. In the case of their monomer states, both emitters exhibit similar emission spectra due to their identical D-A pairs. However, under nondoped conditions, significant improvement in exciton utilization and quenching-resistant features are observed for the molecule with the internal host. The corresponding nondoped OLED yielded a maximum external quantum efficiency of 2.4%, with NIR emission peaking at 765 nm, which was a nearly 10-fold improvement relative to the efficiency based on the control molecule without an internal host. To the best of our knowledge, this result is on par with those of state-of-the art nondoped NIR TADF OLEDs in a similar emission region. These results offer a feasible pathway for the design and development of high-efficiency NIR nondoped OLEDs.

An A-D-A-Type Thermally Activated Delayed Fluorescence Emitter with Intrinsic Yellow Emission Realizing Record-High Red/NIR OLEDs upon Modulating Intermolecular Aggregations.

Realizing efficient red/near-infrared (NIR) electroluminescence (EL) by precisely modulating molecular aggregations of thermally activated delayed fluorescence (TADF) emitters is an attractive pathway, yet the molecular designs are elusive. Here, a new approach is proposed to manage molecular aggregation via a mild-twist acceptor-donor-acceptor (A-D-A)-type molecular design. A proof-of-concept TADF molecule, QCN-PhSAC-QCN, is developed that furnishes a fast radiative rate and obvious aggregation-induced emission feature. Its emission bands can be facilely shifted from intrinsic yellow to the red/NIR region via fine-tuning doping levels and molecular aggregates while maintaining elegant photoluminescence quantum yields benefiting from suppressed exciton annihilation processes. As a result, a QCN-PhSAC-QCN-based organic light-emitting diode (OLED) exhibits a record-setting external quantum efficiency (EQE) of 39.1% at a doping ratio of 10 wt.%, peaking at 620 nm. Moreover, its nondoped NIR OLED affords a champion EQE of 14.3% at 711 nm and retains outstanding EQEs of 5.40% and 2.35% at current densities of 10 and 100 mA cm-2 , respectively, which are the highest values among all NIR-TADF OLEDs at similar density levels. This work validates the feasibility of such mild-twist A-D-A-type molecular design for precisely controlling molecular aggregation while maintaining high efficiency, thus providing a promising pathway for high-performance red/NIR TADF OLEDs.

RGB Thermally Activated Delayed Fluorescence Emitters for Organic Light-Emitting Diodes toward Realizing the BT.2020 Standard.

With the surging demand for ultra-high-resolution displays, the International Telecommunication Union (ITU) announce the next-generation color gamut standard, named ITU-R Recommendation BT.2020, which not only sets a seductive but challenging milestone for display technologies but also urges researchers to recognize the importance of color coordinates. Organic light-emitting diodes (OLEDs) are an important display technology in current daily life, but they face challenges in approaching the BT.2020 standard. Thermally activated delayed fluorescence (TADF) emitters have bright prospects in OLEDs because they possess 100% theoretical exciton utilization. Thus, the development of TADF emitters emitting primary red (R), green (R), and blue (B) emission is of great significance. Here, a comprehensive overview of the latest advancements in TADF emitters that exhibit Commission Internationale de l'Éclairage (CIE) coordinates surpassing the National Television System Committee (NTSC) and approaching BT.2020 standards is presented. Rational strategies for molecular designs, as well as the resulting photophysical properties and OLED performances, are discussed to elucidate the underlying mechanisms for shifting the CIE coordinates of both donor-acceptor and multiple resonance (MR) typed TADF emitters toward the BT.2020 standard. Finally, the challenges in realization of the wide-color-gamut BT.2020 standard and the prospects for this research area are provided.

A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity.

BACKGROUND: Pertuzumab is currently used in combination with trastuzumab as the first-line treatment for HER2-positive metastatic breast cancer. However, pertuzumab was originally developed independently from trastuzumab and was later incidentally found to have synergistic efficacy when combined with trastuzumab, it remains to be seen whether a more potent synergistic efficacy partner exists for trastuzumab. METHODS: A trastuzumab-based functional assay was used to screen anti-HER2 antibodies harboring trastuzumab-synergistic antitumor activity. The lead candidate 5G9, in combination with trastuzumab, was further characterized for its bioactivities in cell proliferation, cell apoptosis, antigen-antibody endocytosis and HER2-mediated cell signaling pathway blocking. Finally, animal models were used to evaluate the in vivo synergistic antitumor efficacy of 5G9 in combination with trastuzumab. FINDINGS: Compared to pertuzumab, 5G9 demonstrated more potent synergistic cell growth inhibitory activity when combined with trastuzumab (85% vs. 55%, P<0.001). In addition, 5G9 exhibited a higher internalization rate than pertuzumab (20% vs. 9%, P<0.05), and was able to further synergize with trastuzumab to promote antigen-antibody endocytosis. The internalization rate of the combination of 5G9 and trastuzumab was higher than that of pertuzumab and trastuzumab (35% vs. 14%, P<0.001). In vivo animal studies demonstrated that 5G9 in combination with trastuzumab showed more potent synergistic antitumor efficacy than the combination of pertuzumab and trastuzumab. INTERPRETATION: 5G9, together with trastuzumab, may provide a potential opportunity for more efficacious treatment of HER2-positive cancers. FUNDING: National Natural Science Foundation of China; State Key Laboratory of Analytical Chemistry for Life Science.

Quantum dots-based immunofluorescent microfluidic chip for the analysis of glycan expression at single-cells.

Rich high-quality single-cell information from rare cell sample is very important for the quantitative systems biology description of cellular function. However, this type of data is often prohibited by the conventional analytical technology such as flow cytometry. In this paper, we described a microfluidic platform coupled with a quantum dots-based (QDs) immunofluorescence (IF) approach to measure the expression of glycans on the cell surface of single cells or cell population. Compared with conventional IF staining, the QDs-based IF probe exhibited higher brightness and stability against photobleaching. With the merits of the novel IF staining protocol and microfluidic platform, high-throughput IF staining was performed to measure the glycan expressions and the changes at single K562 cells after drug treatment. The protocol proposed here showed a high sensitivity on the glycan expression profile owing to the amplification of the signal in indirect IF staining. The size of cell sample was only 4 × 10(3) cells, which made the rare cell sample analysis accessible. This method may find widespread application for assessing cell-surface glycoprotein expression as well as analysis of the heterogeneity in cell populations in a high-throughput manner.

Microfluidic platform for the evaluation of multi-glycan expressions on living cells using electrochemical impedance spectroscopy and optical microscope.

A microfluidic platform to evaluate the expression of multi-glycans on a cell surface was developed using electrochemical impedance spectroscopy (EIS) and optical microscope technique. In the microfluidic channel, four indium tin oxide (ITO) electrodes were modified with three lectins and one passivation agent, respectively, to selectively recognize the corresponding carbohydrate epitopes on the cell surface. The binding of the cells on the electrode array was monitored by the electrochemical impedance to evaluate the expression of cell surface glycans. The excellent optical transparency of ITO electrode permitted the microscopic observation of the cell binding simultaneously to substantiate the impedance measurement. Compared with the individual technology, the double-check mode increased the sensitivity and accuracy of the assay. The experimental results using these two techniques indicated that the cell binding ability decreased in the order WGA > Con A > PNA, which was consistent with the expression difference of carbohydrate epitopes on K562 cell surface. The proposed strategy was further used for facile evaluating the variations of glycan expression on living cells in response to drugs. The consumption of cell sample for each sensing interface in the whole experiments is merely 5 × 10(3) cells. This platform offers great promise for cancer-associated glycol-biomarkers screening and further helps cancer diagnosis and treatment.